Sable Bio secures £2.8m in seed funding from MMC Ventures to scale its drug safety platform.
The seed round was led by MMC Ventures with participation from Episode 1 Ventures and Seedcamp to fund team expansion and product development.
Sable Bio develops an artificial intelligence platform designed to help pharmaceutical companies identify safety risks early in the drug discovery process. The London-based startup provides predictive insights to reduce the risk of clinical trial failures.
Sable Bio has secured £2.8m in seed funding in a round led by MMC Ventures, with participation from existing backers Episode 1 Ventures and Seedcamp. The capital will support team expansion in London, accelerate product development, and integrate real-world evidence into the platform.
Since raising a £2m pre-seed round in late 2023, the startup has secured commercial agreements with multiple pharmaceutical organisations, including three top-ten global pharma firms. The company generates revenue from tools that automate target safety assessments to combat high rates of clinical trial failure.
The fresh funding arrives as pharmaceutical companies increasingly seek automated solutions to parse biomedical data and improve decision-making during early drug discovery.
From the founder
"The pharmaceutical industry has made tremendous strides in AI for hit identification and lead optimisation, but target safety assessment has lagged behind. Sable is positioned to change that by making comprehensive safety data accessible and actionable. We’re thrilled that with this funding, we can build the definitive platform for drug target safety."
Josh Almond-Thynne
co-founder and CEO at Sable Bio
Use of funds
- 01Grow the team
- 02Continue product development
